BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 11, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2019

View Archived Issues

STAT6 siRNA sequences induce apoptosis and proliferation inhibition in colorectal/breast cancer

Read More

XMT-1536 well tolerated in phase I study in patients with solid tumors likely to express NaPi2b

Read More

First-in-human data presented for enapotamab vedotin in patients with advanced cancer

Read More

The BiTE immune-oncology therapeutic pasotuxizumab shows promising efficacy in mCRPC

Read More

Elderly cells found in regenerating organs

Read More

Kinase boost could be strategy for Lewy body busting

Read More

SCO-267, a novel GPR40 full agonist, improves glucose control in rats

Read More

Safety and efficacy of AB-BNCT in recurrent and locally advanced head and neck cancer

Read More

Phase I/IIa study of GEN-009 neoantigen vaccine containing autologous stimulatory peptides

Read More

Increased CCL14 expression linked to chronic kidney disease

Read More

Drug vulnerabilities due to tumor suppressor loss assayed

Read More

Alkermes initiates monotherapy expansion phase of ARTISTRY-1 study of ALKS-4230

Read More

ABBV-085 demonstrates manageable safety and preliminary activity in patients with sarcoma

Read More

Preliminary data presented from first-in-human study of AZD-5153

Read More

Genentech presents phase II data on fenebrutinib for rheumatoid arthritis with inadequate response

Read More

Daiichi Sankyo divulges GLP-1 receptor agonists

Read More

Roche patents gamma-secretase inhibitors

Read More

GemVax & KAEL presents new TGF-beta inhibitors and TNF production inhibitors

Read More

Pharvaris describes bradykinin B2 receptor antagonists

Read More

Dart NeuroScience synthesizes new PDE1B inhibitors

Read More

Topline data from phase III study of Molgradex in autoimmune alveolar pulmonary proteinosis

Read More

Phase IIa study of ALLOB used in lumbar spinal fusion procedure meets primary endpoints

Read More

Phase II study of Lyme disease vaccine candidate VLA-15 enters main study phase

Read More

IDMC recommends continuation of phase III study of masitinib in pancreatic cancer

Read More

IMV announces updated phase II findings for DPX-Survivac in DLBCL

Read More

Allele Biotechnology and Alpine BioTherapeutics enter research agreement on iPSCs for vision loss

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 9, 2026
  • 3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

    Skape Bio unlocks GPCR targets with de novo-designed miniproteins

    BioWorld
    Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
  • Wuxi Apptec signage

    Wuxi Apptec insists it’s ‘not a Chinese military company’

    BioWorld
    Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
  • Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

    BioWorld Science
    Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing